Target intelligence / Profile preview

Serotonin receptor 3 (5-HT3)

Target
5-HT3
Molecular classification
Receptor, Ion channel, Ligand-gated ion channel (Cys-loop family)[1][2][4][6]
01

Overview

Serotonin receptor 3 (5‑HT₃) is a member of the Cys-loop family of ligand-gated ion channels that mediates fast excitatory neurotransmission in both central and peripheral nervous systems. Unlike most other serotonin receptors—which are G protein-coupled—5‑HT₃ forms a pentameric structure surrounding a central cation-selective pore. Functional receptors can be homopentamers composed solely of the A subunit or heteropentamers including B–E subunits; only those containing at least one A subunit are functional. Activation by serotonin leads to rapid membrane depolarization via sodium and potassium influx, triggering neuronal excitation and neurotransmitter release. The primary clinical significance lies in its role as a therapeutic target for antiemetic drugs used to prevent nausea/vomiting associated with chemotherapy or surgery; it also plays roles in pain perception, anxiety regulation, gut motility modulation, and possibly neurodevelopmental processes.[1][2][4]

Other names
5-HT3 receptor5-hydroxytryptamine receptor 3HTR3Htr3a (for the A subunit)Serotonin-gated ion channel receptor5HT3 serotonin receptorSerotonin receptor 3A (for the A subunit)5HT3A[7]
02

Mechanism of action

Antagonists block serotonin binding to the receptor, preventing cation influx, neuronal depolarization, and subsequent neurotransmitter release—this underlies their antiemetic effect. Agonists activate the cation-selective ion channel, leading to rapid neuronal excitation.[1][9]

03

Biological functions

Signal transduction[2]Neuronal excitation and depolarization[2][3]Neurotransmitter release[1][4]
04

Disease associations

Nausea and vomiting (especially chemotherapy-induced)[2]Irritable bowel syndrome[2]Anxiety disorders[10] (Note: The role in neuropsychiatric and gastrointestinal diseases is well established; involvement in other CNS disorders is under investigation.)
05

Safety considerations

Notable safety concerns with antagonists include headache, constipation, QT interval prolongation (risk of arrhythmia), especially with some drugs like ondansetron.[2] There may also be potential CNS effects due to widespread expression.
06

Interacting drugs

Ondansetron[2]

5 more in the full profile.

07

Biomarkers

No widely used clinical biomarkers specific for patient selection or efficacy monitoring of this target are established. However, genetic polymorphisms in HTR3A/HTR3B may influence drug response or disease susceptibility.[3]

Beyond the preview

Go deeper on Serotonin receptor 3 (5-HT3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serotonin receptor 3 (5-HT3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call